The global tramadol HCL market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing investment in research and development activities along with rising technological advancements that will fuel the market growth during the forecast period.
Tramadol HCL is used for the treatment of moderate to severe pain. With the increasing number of surgeries globally, it is expected that it will fuel the growth of the market during the forecast period. The oral form of the tablet comes in both immediate-release and extended-release forms. Tradamol belongs to the opioid agonists class of drugs. The drug alters the way your brain feels the pain, it is equivalent to the biological hormone present in the human brain called endomorphin. The drug binds to receptors which help in decreasing the transmission of pain signals going to the brain.
On September 2021, US FDA approved Tramadol HCL oral liquid for pain management. The drug was developed by Athena Bioscience. Due to the oral liquid form, it offers various benefits such as the dosage titration can be done precisely, people who can’t swallow the pill can use the oral liquid form, and many others. These all factors will fuel the growth of the market during the forecast period. Some of the key global players in the global tramadol HCL market include Atoz Pharmaceuticals, Hexal AG, Grnenthal GmbH, Amneal Pharmaceuticals, Athena Biosciences, and many others.
Market Coverage
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Tramadol HCL Market by Segments
o Intramuscular injection
o Oral
o Rectal Administration
o Hospital
o Clinic
o Medical Centre
Global Tramadol HCL Market by Region
North America
Europe
Asia-Pacific
Rest of the World
REQUEST FOR TABLE
OF CONTENT